Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Para-Iodo-D-Phenylalanine Hydroxamic Acid is a synthetic small molecule and an analog of D-phenylalanine, in which the para position of the phenyl ring is substituted with an iodine atom and the carboxylic acid group is converted to a hydroxamic acid. It has been primarily studied as a biochemical tool and as an inhibitor of metalloproteases, specifically aminopeptidases. Structural studies have shown that it acts as a potent inhibitor by chelating zinc ions at the active site of enzymes such as Aeromonas proteolytica aminopeptidase, stabilizing enzyme-inhibitor complexes through its hydroxamate moiety[9]. There are no known clinical indications or approved therapeutic uses for this compound; it remains experimental and is mainly used in structural biology and enzymology research[4][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on para-iodo-D-phenylalanine hydroxamic acid.